These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 23885194)
1. Development and evaluation of agents for targeting visceral amyloid. Wall JS; Solomon A; Kennel SJ Tijdschr Nucl Geneeskd; 2011 Dec; 33(4):807-814. PubMed ID: 23885194 [TBL] [Abstract][Full Text] [Related]
2. Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy. Wall JS; Williams AD; Foster JS; Richey T; Stuckey A; Macy S; Wooliver C; Campagna SR; Tague ED; Farmer AT; Lands RH; Martin EB; Heidel RE; Kennel SJ Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10839-E10848. PubMed ID: 30377267 [TBL] [Abstract][Full Text] [Related]
3. Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis. Wall JS; Martin EB; Richey T; Stuckey AC; Macy S; Wooliver C; Williams A; Foster JS; McWilliams-Koeppen P; Uberbacher E; Cheng X; Kennel SJ Molecules; 2015 Apr; 20(5):7657-82. PubMed ID: 25923515 [TBL] [Abstract][Full Text] [Related]
4. Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. Wall JS; Kennel SJ; Paulus M; Gregor J; Richey T; Avenell J; Yap J; Townsend D; Weiss DT; Solomon A J Nucl Med; 2006 Dec; 47(12):2016-24. PubMed ID: 17138745 [TBL] [Abstract][Full Text] [Related]
5. The pattern recognition reagents RAGE VC1 and peptide p5 share common binding sites and exhibit specific reactivity with AA amyloid in mice. Kennel SJ; Williams A; Stuckey A; Richey T; Wooliver C; Chazin W; Stern DA; Martin EB; Wall JS Amyloid; 2016; 23(1):8-16. PubMed ID: 26701064 [TBL] [Abstract][Full Text] [Related]
6. Peptide p5 binds both heparinase-sensitive glycosaminoglycans and fibrils in patient-derived AL amyloid extracts. Martin EB; Williams A; Heidel E; Macy S; Kennel SJ; Wall JS Biochem Biophys Res Commun; 2013 Jun; 436(1):85-9. PubMed ID: 23707811 [TBL] [Abstract][Full Text] [Related]
7. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. Wall JS; Richey T; Stuckey A; Donnell R; Macy S; Martin EB; Williams A; Higuchi K; Kennel SJ Proc Natl Acad Sci U S A; 2011 Aug; 108(34):E586-94. PubMed ID: 21807994 [TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a prototypic pan-amyloid clearing agent - a novel murine peptide-immunoglobulin fusion. Foster JS; Balachandran M; Hancock TJ; Martin EB; Macy S; Wooliver C; Richey T; Stuckey A; Williams AD; Jackson JW; Kennel SJ; Wall JS Front Immunol; 2023; 14():1275372. PubMed ID: 37854603 [TBL] [Abstract][Full Text] [Related]
9. Micro-imaging of amyloid in mice. Wall JS; Paulus MJ; Gleason S; Gregor J; Solomon A; Kennel SJ Methods Enzymol; 2006; 412():161-82. PubMed ID: 17046658 [TBL] [Abstract][Full Text] [Related]
10. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. Jager PL; Hazenberg BP; Franssen EJ; Limburg PC; van Rijswijk MH; Piers DA J Nucl Med; 1998 Apr; 39(4):699-706. PubMed ID: 9544684 [TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of p5+14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis. Martin EB; Williams A; Richey T; Stuckey A; Heidel RE; Kennel SJ; Wall JS Sci Rep; 2016 Mar; 6():22695. PubMed ID: 26936002 [TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT. Wall JS; Richey T; Williams A; Stuckey A; Osborne D; Martin E; Kennel SJ Mol Imaging Biol; 2012 Aug; 14(4):402-7. PubMed ID: 22042488 [TBL] [Abstract][Full Text] [Related]
13. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Gillmore JD; Lovat LB; Persey MR; Pepys MB; Hawkins PN Lancet; 2001 Jul; 358(9275):24-9. PubMed ID: 11454373 [TBL] [Abstract][Full Text] [Related]
14. Dynamic PET and SPECT imaging with radioiodinated, amyloid-reactive peptide p5 in mice: a positive role for peptide dehalogenation. Martin EB; Kennel SJ; Richey T; Wooliver C; Osborne D; Williams A; Stuckey A; Wall JS Peptides; 2014 Oct; 60():63-70. PubMed ID: 25102446 [TBL] [Abstract][Full Text] [Related]
15. Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body Ehman EC; El-Sady MS; Kijewski MF; Khor YM; Jacob S; Ruberg FL; Sanchorawala V; Landau H; Yee AJ; Bianchi G; Di Carli MF; Falk RH; Hyun H; Dorbala S J Nucl Med; 2019 Sep; 60(9):1234-1239. PubMed ID: 30954943 [TBL] [Abstract][Full Text] [Related]
16. Pretargeting immunotherapy: a novel treatment approach for systemic amyloidosis. Wall JS; Foster JS; Martin EB; Kennel SJ Pharm Pat Anal; 2017 Sep; 6(5):215-223. PubMed ID: 28825509 [TBL] [Abstract][Full Text] [Related]
17. A binding-site barrier affects imaging efficiency of high affinity amyloid-reactive peptide radiotracers in vivo. Wall JS; Williams A; Richey T; Stuckey A; Huang Y; Wooliver C; Macy S; Heidel E; Gupta N; Lee A; Rader B; Martin EB; Kennel SJ PLoS One; 2013; 8(6):e66181. PubMed ID: 23750281 [TBL] [Abstract][Full Text] [Related]